Fintel reports that on December 5, 2024, Roth MKM initiated coverage of Gain Therapeutics (NasdaqGM:GANX) with a Buy recommendation.
Analyst Price Forecast Suggests 341.40% Upside
As of December 3, 2024, the average one-year price target for Gain Therapeutics is $7.55/share. The forecasts range from a low of $5.05 to a high of $10.50. The average price target represents an increase of 341.40% from its latest reported closing price of $1.71 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Gain Therapeutics is 0MM, an increase of ∞%. The projected annual non-GAAP EPS is -1.49.
What is the Fund Sentiment?
There are 30 funds or institutions reporting positions in Gain Therapeutics. This is an decrease of 10 owner(s) or 25.00% in the last quarter. Average portfolio weight of all funds dedicated to GANX is 0.00%, an increase of 78.78%. Total shares owned by institutions decreased in the last three months by 41.06% to 1,932K shares. 
The put/call ratio of GANX is 0.05, indicating a bullish outlook.
What are Other Shareholders Doing?
DME Capital Management holds 566K shares representing 2.13% ownership of the company. No change in the last quarter.
Gotham Asset Management holds 335K shares representing 1.26% ownership of the company.
Geode Capital Management holds 272K shares representing 1.03% ownership of the company. In its prior filing, the firm reported owning 184K shares , representing an increase of 32.44%. The firm decreased its portfolio allocation in GANX by 0.52% over the last quarter.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 136K shares representing 0.51% ownership of the company. No change in the last quarter.
FSMAX - Fidelity Extended Market Index Fund holds 85K shares representing 0.32% ownership of the company. In its prior filing, the firm reported owning 83K shares , representing an increase of 2.34%. The firm decreased its portfolio allocation in GANX by 60.68% over the last quarter.
Gain Therapeutics Background Information
(This description is provided by the company.)
Gain Therapeutics, Inc. is redefining drug discovery with its See-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
